Adermykon en es it fr

Adermykon Brand names, Adermykon Analogs

Adermykon Brand Names Mixture

  • No information avaliable

Adermykon Chemical_Formula


Adermykon RX_link

No information avaliable

Adermykon fda sheet

Adermykon msds (material safety sheet)

Adermykon MSDS

Adermykon Synthesis Reference

No information avaliable

Adermykon Molecular Weight

2797.3193 g/mol

Adermykon Melting Point

200 - 220 oC

Adermykon H2O Solubility

5.64E+005 mg/L

Adermykon State


Adermykon LogP


Adermykon Dosage Forms

Capsule; Cream; Liquid; Ointment; Powder for solution; Solution; Suspension; Tablet; Tablet (enteric-coated); Tablet (extended-release)

Adermykon Indication

For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Adermykon Pharmacology

Colistin is a polymyxin antibiotic agent. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins.

Adermykon Absorption

Very poor absorption from gastrointestinal tract.

Adermykon side effects and Toxicity

Oral LD50 in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death.

Adermykon Patient Information

No information avaliable

Adermykon Organisms Affected

Gram-negative bacilli